Advertisement

Immunologic Research

, Volume 67, Issue 4–5, pp 450–453 | Cite as

Infliximab therapy for inflammatory colitis in an infant with NEMO deficiency

  • Hasibe ArtacEmail author
  • Ayca Emsen
  • Hulya Ucaryilmaz
  • Halil Haldun Emiroglu
  • Vedat Uygun
  • Asbjørg Stray-Pedersen
Brief Report
  • 40 Downloads

Introduction

X-linked ectodermal dysplasia with immunodeficiency (X-EDA-ID) is a rare disease caused by hypomorphic mutation in the gene encoding nuclear factor-κB (NF-κB) essential modulator (NEMO) [1, 2, 3]. Boys affected with X-EDA-ID have severely impaired host defense, are prone to life-threatening infections, and have susceptibility to atypical mycobacteria. They have also increase risk of inflammatory diseases, in particular inflammatory colitis. NEMO colitis usually occurs early in childhood, causes intractable diarrhea that is difficult to control, and is life-threatening.

A hematopoietic stem cell transplantation (HSCT) reconstitutes the immune cells in NEMO deficiency, but it may worsen non-immune constitutional manifestations, in particular the colitis because of the associated mucosal/epithelial defects that remain after HSCT [4, 5]. TNFα blockage therapy was used as an effective treatment for the intractable NEMO colitis in a few cases [6, 7, 8, 9]. We report here a...

Notes

Acknowledgments

We profoundly thank Dr. Jordan Scott Orange for a great support to diagnose NEMO deficiency in the case.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Hanson EP, et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol. 2008;122:1169–1177.e16.CrossRefGoogle Scholar
  2. 2.
    Aradhya S, Courtois G, Rajkovic A, Lewis RA, Levy M, Israël A, et al. Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma). Am J Hum Genet. 2001;68:765–71.CrossRefGoogle Scholar
  3. 3.
    Pannicke U, Baumann B, Fuchs S, Henneke P, Rensing-Ehl A, Rizzi M, et al. Deficiency of ınnate and acquired ımmunity caused by an IKBKB mutation. N Engl J Med. 2013;369:2504–14.CrossRefGoogle Scholar
  4. 4.
    Klemann C, Pannicke U, Morris-Rosendahl DJ, Vlantis K, Rizzi M, Uhlig H, et al. Transplantation from a symptomatic carrier sister restores host defenses but does not prevent colitis in NEMO deficiency. Clin Immunol. 2016;164:52–6.CrossRefGoogle Scholar
  5. 5.
    Tegtmeyer D, Seidl M, Gerner P, Baumann U, Klemann C. Inflammatory bowel disease caused by primary immunodeficiencies-clinical presentations, review of literature, and proposal of a rational diagnostic algorithm. Pediatr Allergy Immunol. 2017;28:412–29.CrossRefGoogle Scholar
  6. 6.
    Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57:1318–30.CrossRefGoogle Scholar
  7. 7.
    Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr. 2014;59:758–62.CrossRefGoogle Scholar
  8. 8.
    Mizukami T, Obara M, Nishikomori R, Kawai T, Tahara Y, Sameshima N, et al. Nunoi H. Successful treatment with infliximab for inflammatory colitis in a patient with X-linked anhidrotic ectodermal dysplasia with immunodeficiency. J Clin Immunol. 2012;32:39–49.CrossRefGoogle Scholar
  9. 9.
    Yang J, Cheuk DK, Ha SY, Chiang AK, Lee TL, Ho MH, et al. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation. Pediatr Transplant. 2012;16:771–8.CrossRefGoogle Scholar
  10. 10.
    Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Coban Akdemir ZH, et al. Primary immunodeficiency diseases: genomic approaches delineate heterogeneous Mendelian disorders. J Allergy Clin Immunol. 2017;139:232–45.CrossRefGoogle Scholar
  11. 11.
    Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557–61.CrossRefGoogle Scholar
  12. 12.
    Fish JD, Duerst RE, Gelfand EW, Orange JS, Bunin N. Challenges in the use of allogeneic hematopoietic SCT for ectodermal dysplasia with immune deficiency. Bone Marrow Transplant. 2009;43:217–21.CrossRefGoogle Scholar
  13. 13.
    Miot C, Imai K, Imai C, Mancini AJ, Kucuk ZY, Kawai T, et al. Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations. Blood. 2017;130:1456–67.CrossRefGoogle Scholar
  14. 14.
    Nenci A, Huth M, Funteh A, Schmidt-Supprian M, Bloch W, Metzger D, et al. Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum Mol Genet. 2006;15:531–42.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pediatric Immunology and AllergySelcuk University Medical FacultyKonyaTurkey
  2. 2.Department of Gastroenterology and HepatologySelcuk University Medical FacultyKonyaTurkey
  3. 3.Department of Pediatric Hematology and OncologyMedical Park Antalya HospitalAntalyaTurkey
  4. 4.Center for Human Immunobiology-Immunology-Allergy-RhematologyTexas Children Hospital-Baylor College of MedicineHoustonUSA

Personalised recommendations